Author:
Baid Drishti,Lakdawalla Darius N.,Finkelstein Eric A.
Reference29 articles.
1. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines;Salas-Vega;JAMA Oncol,2017
2. Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US;Salas-Vega;Soc Sci Med,2020
3. Willingness to pay for health-related quality of life gains in relation to disease severity and the age of patients;Reckers-Droog;Value Health,2021
4. Health technology assessment with risk aversion in health;Lakdawalla;J Health Econ,2020
5. Considering severity in health technology assessment: can we do better?;Skedgel;Value Health,2022